Traws Pharma defers Phase 2a test of tivoxavir marboxil after UK MHRA review

Traws Pharma, Inc.

Phase 2a human influenza challenge study for TXM deferred due to negative UK MHRA review.
Tivoxavir marboxil retains potential for emergency bird flu use per CSO Pauza.
Company advancing backup influenza candidates with TXM's PK profile and no mutagenic potential.
Cash runway extends to Q1 2027; CEO confirms commitment to long-acting influenza antivirals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.